Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

NCT06041529 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
DRUG: Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg

Sponsor

Yuhan Corporation